MOUNTAIN VIEW, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, recently announced that deCODE genetics, a leading biopharmaceutical company, has become a customer for the Drug Model Explorer (DMX). The license agreement with deCODE is the latest Pharsight has closed with leading pharmaceutical companies in Europe and the United States.
DMX is a software tool that allows clinical drug development teams to quickly and efficiently explore the modeled efficacy, safety, and other performance attributes of a new drug versus competing therapies.
“We hope to use DMX to drive faster and more confident drug-development decisions at deCODE,” said David Hermann, PharmD, Executive Director of Pharmacometrics at deCODE. “We expect to use DMX to rapidly display our latest modeling results and make our development decisions clear to the entire team.”
Daniel L. Hartman, M.D., Senior Vice President of Product Development at deCODE added, “Quantitative modeling and simulation offers a valuable set of approaches to help navigate the myriad trade-offs and complexities that inform key program decisions. We look forward to using DMX to explore model-based results and support the decision-making process for promising therapies in our pipeline.”
About DMX
DMX can enhance the entire development team’s understanding of a drug’s likely clinical potential and limitations, and enable more efficient decision-making by providing direct interaction with modeling results presented as a series of intuitive plots and tables. Pharsight believes that DMX will help increase the usage of quantitative-based decision-making in the drug development process.
“DMX’s intuitive presentation of modeling insights is especially useful when a new drug faces tough competition,” said Shawn O’Connor, Pharsight president and chief executive officer. “We are pleased that deCODE recognizes the contribution that quantitative drug-disease modeling, combined with novel visualization and communication technology like DMX, can make to improve decision-making.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
About deCODE genetics
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs for common diseases. deCODE is a global leader in gene discovery -- its population approach and resources have enabled the company to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, providing drug targets rooted in the basic biology of disease. The company currently has eight lead programs in drug discovery and development, including three in clinical trials, and is broadening its pipeline through gene and target discovery work in 50 of the most common diseases. Further information on deCODE Genetics is available at www.decode.com.
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding anticipated performance of Pharsight’s products and the expected benefits to customers from the use of such products. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including general market and business conditions, uncertainties involved in pharmaceutical drug development, changes in the demand for Pharsight’s products, the failure to develop new services or to keep pace with technological changes, the failure of Pharsight’s services to obtain anticipated levels of customer acceptance or to meet customers’ expectations, and changes in government regulation of the pharmaceutical industry. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 14, 2005. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Registered Trademarks and Trademarks
Pharsight(R) and DMX(R) are registered trademarks of Pharsight Corporation. Drug Model Explorer(TM) is a trademark of Pharsight Corporation.
All other brand and product names are trademarks or registered trademarks of their respective holders.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, or Jennifer Beugelmans, both at+1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, all of EVCGroup, for Pharsight
